Trial Profile
A Pilot Study of the Effect of Erlotinib (Tarceva) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1 alpha.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Biomarker; Therapeutic Use
- 03 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 03 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT01654757).